The effect of systemic acetazolamide administration on intraocular pressure in healthy horses-A preliminary study.
carbonic anhydrase inhibitors
equine glaucoma
Journal
Veterinary ophthalmology
ISSN: 1463-5224
Titre abrégé: Vet Ophthalmol
Pays: England
ID NLM: 100887377
Informations de publication
Date de publication:
05 Jun 2024
05 Jun 2024
Historique:
revised:
10
05
2024
received:
02
08
2023
accepted:
15
05
2024
medline:
6
6
2024
pubmed:
6
6
2024
entrez:
5
6
2024
Statut:
aheadofprint
Résumé
In equine glaucoma, topical treatment with carbonic anhydrase inhibitors (CAIs) is recommended. Oral acetazolamide, a systemic CAI, is used in horses with hyperkalemic periodic paralysis. Information regarding its effect on equine intraocular pressure (IOP) is scarce. The aim of the study was to determine the effect of oral acetazolamide treatment on IOP in horses, in a case-control study. Ten healthy horses. Horses were treated with oral acetazolamide (4.4 mg/kg) BID for 1 week. Serum acetazolamide concentrations were determined by liquid chromatography/tandem mass spectrometry, and IOP were measured before treatment, daily during treatment, and at 48 and 72 h after treatment. Acetazolamide serum levels reached steady state at 72 h after the first oral dose. In a mixed effect model logistic regression, there was a significant decrease in IOP on the third treatment day, of 2.4 mmHg (p = .012) and 2.7 mmHg (p = .006) in the left (OS) and right eye (OD), respectively. On the seventh day, there was a decrease in 2.5 mmHg (p = .008) and 2.7 mmHg (p = .007) OS and OD, respectively. A significant increase occurred 48 h following treatment discontinuation (3.6 mmHg, p < .001 and 3.5 mmHg, p < .001 OS and OD, respectively). The area under the concentration versus time curve (AUC Further studies are required to determine whether acetazolamide is a potential treatment for equine glaucoma.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Veterinary Ophthalmology published by Wiley Periodicals LLC on behalf of American College of Veterinary Ophthalmologists.
Références
Michau TM. Equine glaucoma. Vet Clin North Am Equine Pract. 2007;33:519‐540.
Gerding JC, Gilger BC. Prognosis and impact of equine recurrent uveitis. Equine Vet J. 2016;48:290‐298.
Wilkie DA, Gilger BC. Equine glaucoma. Vet Clin North Am Equine Pract. 2004;20:381‐391.
Maślanka T. A review of the pharmacology of carbonic anhydrase inhibitors for the treatment of glaucoma in dogs and cats. Vet J. 2015;203:278‐284.
Beech J, Lindborg S. Prophylactic efficacy of phenytoin, acetazolamide and hydrochlorothiazide in horses with hyperkalaemic periodic paralysis. Res Vet Sci. 1995;59:95‐101.
Alberts MK, Clarke CR, MacAllister CG, Homer LM. Pharmacokinetics of acetazolamide after intravenous and oral administration in horses. Am J Vet Res. 2000;61:965‐968.
Vengust M, Staempfli H, Viel L, Heigenhauser G. Effects of chronic acetazolamide administration on fluid flux from the pulmonary vasculature at rest and during exercise in horses. Equine Vet J. 2006;38:508‐515.
Vengust M, Stämpfli H, De Moraes AN, et al. Effects of chronic acetazolamide administration on gas exchange and acid‐base control in pulmonary circulation in exercising horses. Equine Vet J Suppl. 2010;42:40‐50.
Wilkie DA. Equine glaucoma: state of the art. Equine Vet J. 2010;42:62‐68.
Valberg SJ. Genetics of equine muscle disease. Vet Clin North Am Equine Pract. 2020;36:353‐378.
Traub‐Dargatz JL, Ingram JT, Stashak TS, et al. Respiratory stridor associated with polymyopathy suspected to be hyperkalemic periodic paralysis in four quarter horse foals. J Am Vet Med Assoc. 1992;201:85‐89.
Yáñez JA, Remsberg CM, Sayre CL, Forrest ML, Davies NM. Flip‐flop pharmacokinetics – delivering a reversal of disposition: challenges and opportunities during drug development. Ther Deliv. 2011;2:643‐672.
Ito S. Pharmacokinetics 101. Paediatr Child Health. 2011;16:535‐536.
Schmickl CN, Owens RL, Orr JE, Edwards BA, Malhotra A. Side effects of acetazolamide: a systematic review and meta‐analysis assessing overall risk and dose dependence. BMJ Open Respir Res. 2020;7:e000557.
Ibrahim A, Hussain N. Brief report: Metabolic acidosis in newborn infants following maternal use of acetazolamide during pregnancy. J Neonatal Perinatal Med. 2020;13:419‐425.
Vengust M, Staempfli H, Viel L, Swenson ER, Heigenhauser G. Acetazolamide attenuates transvascular fluid flux in equine lungs during intense exercise. Physiol J. 2013;591:4499‐4513.